Table 2

Predictive clinical baseline factors for successful down-titration

Predictive factor	OR	95% CI	Pseudo R2	Prob>χ²
RF (negative/positive)	1.3	0.30 to 5.57	0.0018	0.72
Anti-CCP (negative/positive)	0.7	0.16 to 3.18	0.0035	0.64
Age (years)	1.0	0.95 to 1.05	0.0000	0.98
Sex (male/female)	1.1	0.36 to 3.51	0.0007	0.83
Smoking (no/yes)	5.3	0.59 to 46.6	0.0454	0.08
Disease duration (years)	0.9	0.86 to 1.01	0.0392	0.10
DAS28 at start	0.6	0.26 to 1.21	0.0345	0.12
Duration of infliximab therapy (years)	0.9	0.73 to 1.15	0.0081	0.46
Methotrexate use (no/yes)	1.3	0.40 to 4.38	0.0029	0.65
DMARD use (no/yes)	1.0	0.25 to 4.28	0.0000	0.95
Patient's belief on successful down-titration (no/yes)	2.4	0.71 to 7.76	0.0292	0.16

Anti-CCP, anti-cyclic citrullinated peptide; DAS28, 28-joint disease activity score; DMARD, disease-modifying antirheumatic drugs, RF, rheumatoid factor.